Cybrexa Therapeutics is developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment. This approach leverages a novel tumor-localizing peptide technology developed by an internationally recognized research laboratory at Yale. Our approach will change the paradigm of drug delivery, and itwill greatly enhance the therapeutic index. It has the potential to re-define the definition of “drug-like,” which will unlock a vast array of molecules for clinical development. Our collection of tumor-localizing DNA repair inhibitors can be combined with numerous chemotherapies and also radiotherapy, allowing the safe delivery of higher drug doses, with enhanced efficacy.

Therapeutics

Pharmaceutical

Biotechnology

Cybrexa Therapeutics

Per Hellsund

Jaya Gautam

Laurie Kenvin

Vishwas Paralkar

Ranjit Bindra

Mike Needle

The Leadership Team at Cybrexa Therapeutics drives the strategic vision and operational execution of the company's innovative approach to cancer therapy. Comprised of top executives with expertise in science, medicine, and clinical operations, this team is responsible for overseeing research initiatives, guiding clinical development, and ensuring regulatory compliance. Their collective efforts aim to leverage the company's unique tumor-localizing peptide technology to revolutionize drug delivery, enhance therapeutic outcomes, and ultimately improve patient outcomes in cancer treatment.

Leadership Team

Research and Development Team

Leadership Team

About

Team members

Other teams at Cybrexa Therapeutics

Research and Development Team